Divi’s Laboratories is a niche player in the pharma space and the company’s product portfolio comprises two broad segments—generic active pharmaceutical ingredients (APIs) and custom synthesis of APIs. Also, it has presence in nutraceuticals and synthesis of speciality ingredients for its clients.
Why: The company is expected to be a major beneficiary of increased outsourcing opportunities driven by its expertise in complex chemistry, cost efficient processes and relationship with global pharma majors.
What: Currency volatility could impact earnings
